Gain Therapeutics (GANX) Held by Superinvestors
GAIN THERAPEUTICS INC (GANX) is currently held by 2 superinvestors tracked by InsiderSet, with a combined reported market value of approximately $3.07M based on the latest available SEC Form 13F filings for the quarter ended December 31, 2023.
Greenlight Capital is currently the largest disclosed institutional shareholder of GANX tracked by InsiderSet, reporting ownership valued at approximately $1.92M in its December 31, 2023 SEC Form 13F filing. Based on current market prices and the latest disclosed share count, the position is now estimated to be worth approximately $664,903.3, representing an estimated loss of -65.39% since the filing period.
The top 10 institutional shareholders tracked on this page collectively account for approximately 100% of the total disclosed GANX value among the investors covered in this analysis. Major shareholders include Greenlight Capital, Greenlight Capital, and several other long-term asset managers with concentrated positions in GAIN THERAPEUTICS INC (GANX).
This page ranks the largest institutional GANX shareholders using publicly disclosed SEC Form 13F data, including reported values, estimated current holding values, portfolio allocation percentages, ownership concentration metrics, and historical holding changes across major hedge funds and investment firms.
| Name | Investor/Manager | Portfolio % | Quantity | Reported Balance | Current Estimated Value | Gain/loss Since Filing | Estimated Portfolio Performance |
|---|---|---|---|---|---|---|---|
| Greenlight Capital | David Einhorn | 0.09% | 588,410 | $1,921,158 | $664,903 | -$1,256,255 | -65.39% |
| Greenlight Capital | David Einhorn | 0.03% | 566,130 | $1,149,244 | $639,727 | -$509,517 | -44.33% |
Frequently asked questions about GANX
Who are the largest superinvestors holding GANX?
The largest superinvestors holding GANX in the latest SEC Form 13F filings include Greenlight Capital and Greenlight Capital. InsiderSet ranks these superinvestors by their latest reported GANX position.
What does the GANX superinvestors page include?
This page tracks GANX positions reported by a curated group of notable institutional investors and fund managers through SEC Form 13F. GAIN THERAPEUTICS INC (GANX) on this page reflects disclosed 13F holdings among those superinvestors, not every institutional shareholder of the stock.
How many superinvestors hold GANX?
InsiderSet currently tracks 2 superinvestors reporting GANX holdings in the latest available 13F data. This is the curated set on this page, not the total number of institutions that own GANX.
How much GANX stock do superinvestors hold?
Superinvestors tracked by InsiderSet disclosed approximately $3.07M in GANX holdings for Q4 2023. This figure is reported 13F value as of the filing period, not necessarily today's market value, and it covers the curated superinvestors on this page rather than every institutional filer.
When were GANX superinvestor holdings last updated?
The latest GANX superinvestor holdings on InsiderSet are based on SEC Form 13F filings for the quarter ended December 31, 2023. Form 13F filings are generally reported after the quarter ends, so the holdings shown represent the latest publicly disclosed positions rather than real-time holdings.
Are superinvestor GANX holdings real-time?
No. Form 13F data is not real-time. It represents positions reported by these superinvestors as of the end of the reporting quarter. A superinvestor may have changed its GANX position after the reporting date.
Are superinvestors buying or selling GANX?
Buying and selling can be analyzed by comparing GANX positions across consecutive 13F reporting periods. InsiderSet's GANX Ownership Changes page shows institutions that increased, reduced, initiated, or exited positions based on reported 13F holdings. View GANX ownership changes.
How have superinvestor GANX holdings changed over time?
InsiderSet tracks GANX holdings among these superinvestors across multiple 13F reporting periods, so holder counts, reported value, and reported shares can be compared over time.